Ventrus Biosciences (VTUS)
Ventrus Biosciences Cash and ST Investments: 53.29M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
VTUS Cash and ST Investments Rankings
| Overall | 41st percentile | 2566 of 4368 |
| Sector | 49th percentile | 256 of 506 in Healthcare |
| Industry | 36th percentile | 16 of 25 in Drug Manufacturers - Major |
VTUS Cash and ST Investments Range, Past 5 Years
| Minimum | 11.36M | Jun 2011 |
| Maximum | 53.29M | Sep 2011 |
| Average | 26.22M |
About Cash and Short Term Investments
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities
Learn More
You may also be interested in these VTUS related companies
VTUS News
$KERX solid volume pushing higher so far. $amrn $arna holding up. $vtus looking to add
about a day ago by ITradeforMe
about a day ago by ITradeforMe
Ventrus to Present at the Jefferies 2012 Global Healthcare Conference $VTUS http://stks.co/428w
about 2 days ago by ventrusbio
about 2 days ago by ventrusbio
$VTUS undervalued stock that can gain upto 200% in a year, great ph3 results announced recently, target 29$ $$
about 3 days ago by peterumble
about 3 days ago by peterumble
$VTUS up 9% from 10.01 when tweeted buying in morning, target 29$, get long this co., posted
about 11 days ago by peterumble
about 11 days ago by peterumble
RT @Singe: but $VTUS chart looks like crap and $VVUS chart is slowly on way to 25 where it could break.//Buy at bottom not at top #MONEY $$
about 11 days ago by peterumble
about 11 days ago by peterumble
@peterumble but the $VTUS chart looks like crap and the $VVUS chart is slowly on the way to 25 where it could break out this time.
about 11 days ago by Singe
about 11 days ago by Singe
$VTUS adding again as stock is damn cheap at 10 after positive ph 3 results last week, avg price target is 29$, 300% upside $$
about 11 days ago by peterumble
about 11 days ago by peterumble
$AMRN Marine 889 patent prosecution update http://stks.co/3tFJ $ARRY $GALE $VTUS $PFE $KERX
about 14 days ago by imhobutdydd
about 14 days ago by imhobutdydd
@Szw go read up FDA approval process. $vtus hasn't even submitted an NDA yet. That means at this point it'll be a ~year if they apply now
about 14 days ago by elysian
about 14 days ago by elysian
$AMRN Marine 889 patent prosecution update http://stks.co/3soe $ARRY $GALE $VTUS $PFE $KERX
about 15 days ago by imhobutdydd
about 15 days ago by imhobutdydd
Ventrus to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 15, 7:00AM GlobeNewswire
May 15, 7:00AM GlobeNewswire
Morning Movers 05/14: (GOLF) (VTUS) (KERX) Higher; (IOC) (ACOM) (ANIK) Lower
May 14, 10:07AM Street Insider
May 14, 10:07AM Street Insider
Ventrus to Present at the 37th Annual Deutsche Bank Health Care Conference
May 01, 8:30AM GlobeNewswire
May 01, 8:30AM GlobeNewswire
Cantor Fitzgerald Starts Ventrus Biosciences (VTUS) at Buy; N-T Binary Play
Apr 05, 7:11AM Street Insider
Apr 05, 7:11AM Street Insider
Ventrus Announces Two Studies Addressing Hemorrhoid Disease to be Presented at Digestive Disease Week Conference
Mar 08, 8:30AM GlobeNewswire
Mar 08, 8:30AM GlobeNewswire
Ventrus to Present at Cowen and Company 32nd Annual Health Care Conference
Feb 28, 8:30AM GlobeNewswire
Feb 28, 8:30AM GlobeNewswire
Ventrus BioSciences (VTUS) Publicizes Prior Phase 2b Study on the Safety and Efficacy of Iferanserin
Jan 13, 3:01PM Street Insider
Jan 13, 3:01PM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| VTUS | 9.86 | -0.25 | -2.47% | 125.47M |
| VTROD | 1.30 | +0.00 | +0.00% | |
| VTR | 57.09 | -1.73 | -2.94% | 16.99B |
| VTNC | 6.58 | -0.42 | -6.00% | 114.31M |
| VTN | 15.92 | -0.04 | -0.25% | |
| VTJ | 18.17 | +0.07 | +0.39% | |
| VTI | 65.93 | -1.40 | -2.08% | |
| VTA | 11.52 | -0.05 | -0.43% | |
| VT | 42.65 | -0.79 | -1.82% | |
| VSTA | 2.80 | -0.19 | -6.35% |
